{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-2894"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-2894","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Thymidine phosphorylase is a promising target in SARS-CoV-2 spike protein-enhanced thrombosis","abstract":"Thrombosis, as an underlying mechanism in cardiovascular diseases, is the leading global cause of death in the 21st century. Infection is a risk factor for thrombosis, and the coronavirus disease 2019 (COVID-19) pandemic has led to a rise in the incidence of thrombosis, thereby increasing mortality. In comparison to previous severe coronavirus outbreaks, rates of thrombosis in COVID-19 have been unprecedented. COVID-19 is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 spike protein (SP), the key used to enter host cells, is implicated in thrombosis pathology, though mechanisms are not fully understood. The SARS-CoV-2 SP may also be involved in vaccine-induced immune thrombotic thrombocytopenia (VITT), a reaction to COVID-19 vaccination where deadly thromboses materialize. Discovering mechanism-based therapies for life-threatening diseases is paramount in minimizing off-target effects and maximizing positive responses to treatment. Thymidine phosphorylase (TYMP), a pyrimidine salvage pathway enzyme with novel prothrombotic function, has been identified by our lab as a target in COVID-19-associated thrombosis. This dissertation investigates SARS-CoV-2 SP-associated thrombosis using animal models, human tissue, blood studies, cell culture, and in-silico modeling, and shows the effectiveness of targeting TYMP to attenuate SP-promoted thrombosis. This dissertation aims to address knowledge gaps concerning the mechanistic impact of SP on thrombosis, establish a foundation for targeting TYMP as a potential therapeutic avenue, and unveil a novel interaction between SP and platelet factor 4 (PF4), which may bear implications for COVID-19-associated thrombosis and/or VITT.","abstract_html":"Thrombosis, as an underlying mechanism in cardiovascular diseases, is the leading global cause of death in the 21st century. Infection is a risk factor for thrombosis, and the coronavirus disease 2019 (COVID-19) pandemic has led to a rise in the incidence of thrombosis, thereby increasing mortality. In comparison to previous severe coronavirus outbreaks, rates of thrombosis in COVID-19 have been unprecedented. COVID-19 is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 spike protein (SP), the key used to enter host cells, is implicated in thrombosis pathology, though mechanisms are not fully understood. The SARS-CoV-2 SP may also be involved in vaccine-induced immune thrombotic thrombocytopenia (VITT), a reaction to COVID-19 vaccination where deadly thromboses materialize. Discovering mechanism-based therapies for life-threatening diseases is paramount in minimizing off-target effects and maximizing positive responses to treatment. Thymidine phosphorylase (TYMP), a pyrimidine salvage pathway enzyme with novel prothrombotic function, has been identified by our lab as a target in COVID-19-associated thrombosis. This dissertation investigates SARS-CoV-2 SP-associated thrombosis using animal models, human tissue, blood studies, cell culture, and in-silico modeling, and shows the effectiveness of targeting TYMP to attenuate SP-promoted thrombosis. This dissertation aims to address knowledge gaps concerning the mechanistic impact of SP on thrombosis, establish a foundation for targeting TYMP as a potential therapeutic avenue, and unveil a novel interaction between SP and platelet factor 4 (PF4), which may bear implications for COVID-19-associated thrombosis and/or VITT.","abstract_has_math":false,"creators":["Roytenberg, Renat"],"institution":null,"degree_name":"Biomedical Research","degree_level":"Dissertation","degree_discipline":"Joan C. Edwards School of Medicine","degree_department":null,"school":null,"contributors":["Dr. Wei Li, Committee Chairperson","Dr. Ji Bihl","Dr. Adolfo Garcia-Sastre"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:10Z","subjects":["Biology","Cell and Developmental Biology","Cell Biology","Molecular Biology","COVID-19","Platelet factor 4","Spike protein","Thrombosis","Thymidine phosphorylase"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1889","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1889","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-2894","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Wei Li, Committee Chairperson","Dr. Ji Bihl","Dr. Adolfo Garcia-Sastre"]},{"key":"dc:creator","label":"Author","values":["Roytenberg, Renat"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2024-12-10T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2024-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Joan C. Edwards School of Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Biomedical Research"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biology","Cell and Developmental Biology","Cell Biology","Molecular Biology","COVID-19","Platelet factor 4","Spike protein","Thrombosis","Thymidine phosphorylase"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1889"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Thrombosis, as an underlying mechanism in cardiovascular diseases, is the leading global cause of death in the 21st century. Infection is a risk factor for thrombosis, and the coronavirus disease 2019 (COVID-19) pandemic has led to a rise in the incidence of thrombosis, thereby increasing mortality. In comparison to previous severe coronavirus outbreaks, rates of thrombosis in COVID-19 have been unprecedented. COVID-19 is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 spike protein (SP), the key used to enter host cells, is implicated in thrombosis pathology, though mechanisms are not fully understood. The SARS-CoV-2 SP may also be involved in vaccine-induced immune thrombotic thrombocytopenia (VITT), a reaction to COVID-19 vaccination where deadly thromboses materialize. Discovering mechanism-based therapies for life-threatening diseases is paramount in minimizing off-target effects and maximizing positive responses to treatment. Thymidine phosphorylase (TYMP), a pyrimidine salvage pathway enzyme with novel prothrombotic function, has been identified by our lab as a target in COVID-19-associated thrombosis. This dissertation investigates SARS-CoV-2 SP-associated thrombosis using animal models, human tissue, blood studies, cell culture, and in-silico modeling, and shows the effectiveness of targeting TYMP to attenuate SP-promoted thrombosis. This dissertation aims to address knowledge gaps concerning the mechanistic impact of SP on thrombosis, establish a foundation for targeting TYMP as a potential therapeutic avenue, and unveil a novel interaction between SP and platelet factor 4 (PF4), which may bear implications for COVID-19-associated thrombosis and/or VITT."]},{"key":"dc:title","label":"Title","values":["Thymidine phosphorylase is a promising target in SARS-CoV-2 spike protein-enhanced thrombosis"]}]}],"canonical_facts":{"dc:contributor":["Dr. Wei Li, Committee Chairperson","Dr. Ji Bihl","Dr. Adolfo Garcia-Sastre"],"dc:creator":["Roytenberg, Renat"],"dc:date.available":["2024-12-10T08:00:00Z"],"dc:date.created":["2024-01-01T08:00:00Z"],"dc:description.abstract":["Thrombosis, as an underlying mechanism in cardiovascular diseases, is the leading global cause of death in the 21st century. Infection is a risk factor for thrombosis, and the coronavirus disease 2019 (COVID-19) pandemic has led to a rise in the incidence of thrombosis, thereby increasing mortality. In comparison to previous severe coronavirus outbreaks, rates of thrombosis in COVID-19 have been unprecedented. COVID-19 is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 spike protein (SP), the key used to enter host cells, is implicated in thrombosis pathology, though mechanisms are not fully understood. The SARS-CoV-2 SP may also be involved in vaccine-induced immune thrombotic thrombocytopenia (VITT), a reaction to COVID-19 vaccination where deadly thromboses materialize. Discovering mechanism-based therapies for life-threatening diseases is paramount in minimizing off-target effects and maximizing positive responses to treatment. Thymidine phosphorylase (TYMP), a pyrimidine salvage pathway enzyme with novel prothrombotic function, has been identified by our lab as a target in COVID-19-associated thrombosis. This dissertation investigates SARS-CoV-2 SP-associated thrombosis using animal models, human tissue, blood studies, cell culture, and in-silico modeling, and shows the effectiveness of targeting TYMP to attenuate SP-promoted thrombosis. This dissertation aims to address knowledge gaps concerning the mechanistic impact of SP on thrombosis, establish a foundation for targeting TYMP as a potential therapeutic avenue, and unveil a novel interaction between SP and platelet factor 4 (PF4), which may bear implications for COVID-19-associated thrombosis and/or VITT."],"dc:identifier":["https://mds.marshall.edu/etd/1889"],"dc:subject":["Biology","Cell and Developmental Biology","Cell Biology","Molecular Biology","COVID-19","Platelet factor 4","Spike protein","Thrombosis","Thymidine phosphorylase"],"dc:title":["Thymidine phosphorylase is a promising target in SARS-CoV-2 spike protein-enhanced thrombosis"],"thesis:degree_discipline":["Joan C. Edwards School of Medicine"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Biomedical Research"]},"updated_at":"2026-11-21T19:58:10Z"}